TMO EPM / Hemato H9J
by TMO EPM / Hemato H9J
Latest episode
94 - Cladribine With Low-Dose Cytarabine and Venetoclax Alternating…
94 - Cladribine With Low-Dose Cytarabine and Venetoclax Alternating…
About this podcast
Podcast de discussão de assuntos em Hematologia do Transplante de Medula Óssea da Escola Paulista de Medicina (UNIFESP) e da Hematologia do Hospital 9 de Julho - DASA
Episodes
The newest 20 of 94 episodes
- 94 - Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed AML (Kadia TM et al., Am J Hematol 2026) · 31 minCladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Kadia TM et al., Am J Hematol 2026. doi…
- 93 - Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL (GIMEMA ALL2820, N Engl J Med 2026) · 33 minPonatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL. Chiaretti S et al., N Engl J Med 2026;395:1483-94. doi 10.1056/NEJMoa2606208 Ensaio de fase 3 (GIMEMA…
- 92 - Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma (ENDURANCE, N Engl J Med 2026) · 31 minContinuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma. Kumar S et al., N Engl J Med 2026;395:221-32. doi 10.1056/NEJMoa2600157 Ensaio de fase 3 (ENDURANCE…
- 91 - Bridging Therapy Response and Type as Determinants of Cilta-cel Outcomes in Relapsed-Refractory Multiple Myeloma (Blood Cancer J 2026) · 32 minDiscussão do estudo de Hansen DK et al. (Blood Cancer J 2026): coorte retrospectiva de um único centro (Moffitt Cancer Center) com 192 pacientes com mieloma múltiplo recaído ou…
- 90 - Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma (SUNMO, J Clin Oncol 2025) · 24 minDiscussão do SUNMO (Budde LE et al., J Clin Oncol 2025): ensaio randomizado de fase 3 que comparou mosunetuzumabe (bispecífico CD20×CD3) + polatuzumabe vedotina (anticorpo…
- 89 - Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia (PARADIGM, N Engl J Med 2026) · 35 minDiscussão do PARADIGM (Fathi AT et al., N Engl J Med 2026): ensaio randomizado de fase 2 que comparou azacitidina + venetoclax com quimioterapia de indução intensiva em 172…
- 88 - Haploidentical Bone Marrow Transplantation for Sickle Cell Disease (BMT CTN 1507, NEJM Evidence 2025) · 26 minDiscussão do BMT CTN 1507 (Kassim AA et al., NEJM Evidence 2025): estudo de fase 2, braço único e multicêntrico (19 centros dos EUA) de transplante de medula óssea haploidêntico…
- 87 - Tafasitamab + lenalidomide + R-CHOP vs R-CHOP in high-risk DLBCL (frontMIND, Lancet 2026) · 30 minDiscussão do frontMIND (Lenz G et al., The Lancet 2026): estudo de fase 3, duplo-cego e controlado por placebo, que comparou tafasitamabe + lenalidomida + R-CHOP com R-CHOP em…
- 86 - Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial · 29 min · Season 1 Episode 86Discussão do artigo: "Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III…
- 85 - Non-Myeloablative versus Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged ≥65: A Study from the ALWP of EBMT · 29 min · Season 1 Episode 85Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP…
- 84 - High-Dose Busulfan-Melphalan vs. Melphalan and Reinforced VRD in Newly Diagnosed Multiple Myeloma. A Phase III GEM Trial · 25 min · Season 1 Episode 84Neste episódio discutimos o condicionamento do transplante autólogo no mieloma múltiplo recém-diagnosticado: bussulfano-melfalano em altas doses (BUMEL) versus melfalano 200…
- 83 - Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia · 36 min · Season 1 Episode 83Neste episódio discutimos o condicionamento de intensidade reduzida (RIC) com TBI 8 Gy antes do transplante alogênico de células-tronco hematopoéticas em adultos com leucemia…
- 82 - All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia · 29 min · Season 1 Episode 82Neste episódio discutimos o ASCERTAIN-V — um esquema 100% oral (decitabina-cedazuridina + venetoclax) para leucemia mieloide aguda (LMA) recém-diagnosticada em pacientes…
- 81 - Carfilzomib, lenalidomide, dexamethasone vs lenalidomide after autologous HSCT in multiple myeloma (ATLAS): phase 3 trial · 23 min · Season 1 Episode 81Neste episódio discutimos o ATLAS — carfilzomibe, lenalidomida e dexametasona (KRd) versus lenalidomida isolada como manutenção após transplante autólogo (ASCT) no mieloma…
- 80 - Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial · 42 min · Season 1 Episode 80Neste episódio discutimos o RELAZA2 — os resultados finais e de longo prazo do uso da azacitidina preemptiva guiada por DRM para prevenir recaída em LMA e SMD de alto risco…
- 79 - Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial · 27 min · Season 1 Episode 79Journal club do TMO EPM (EPM-Unifesp / Hospital Nove de Julho). Neste episódio discutimos o CARTITUDE-4 — a análise atualizada, incluindo sobrevida global, do ensaio fase 3 que…
- 78 - Three-Hour Infusion of Methotrexate at 3 g/m² With or Without Intrathecal Chemotherapy Reduces CNS Relapses and Improves Survival in Large B-Cell Lymphomas at Increased CNS Risk · 22 min · Season 1 Episode 78Discussão do artigo: "Three-Hour Infusion of Methotrexate at 3 g/m² With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients…
- 77 - Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma · 31 min · Season 1 Episode 77Discussão do artigo: "Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma" (estudo MajesTEC-3) de Costa LJ, Mateos MV et al., NEJM 2026;394:739-752…
- 76 - Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial · 35 min · Season 1 Episode 76Discussão do artigo: "Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial"…
- 75 - Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 33 min · Season 1 Episode 75Discussão do artigo: "Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma" de Woyach J JCO 2025…







